Quentec Asset Management Position in Vivint Solar (VSLR) Lowered by $1.79 Million; As Agios Pharmaceuticals (AGIO) Valuation Declined, Redmile Group Lowered Its Position

November 24, 2017 - By Henry Gaston

Jeremy Green decreased its stake in Agios Pharmaceuticals Inc (AGIO) by 24.53% based on its latest 2017Q2 regulatory filing with the SEC. Redmile Group Llc sold 221,413 shares as the company’s stock declined 9.11% while stock markets rallied. The hedge fund run by Jeremy Green held 681,165 shares of the health care company at the end of 2017Q2, valued at $35.05 million, down from 902,578 at the end of the previous reported quarter. Redmile Group Llc who had been investing in Agios Pharmaceuticals Inc for a number of months, seems to be less bullish one the $2.99 billion market cap company. The stock increased 1.86% or $1.12 on November 22, reaching $61.3. About shares traded. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has risen 8.52% since November 24, 2016 and is uptrending. It has underperformed by 8.18% the S&P500.

Quentec Asset Management Llc decreased its stake in Vivint Solar Inc (VSLR) by 10.1% based on its latest 2017Q2 regulatory filing with the SEC. Quentec Asset Management Llc sold 357,757 shares as the company’s stock declined 9.09% while stock markets rallied. The hedge fund held 3.18 million shares of the capital goods company at the end of 2017Q2, valued at $18.62M, down from 3.54 million at the end of the previous reported quarter. Quentec Asset Management Llc who had been investing in Vivint Solar Inc for a number of months, seems to be less bullish one the $412.07 million market cap company. It closed at $3.6 lastly. It is down 29.31% since November 24, 2016 and is uptrending. It has outperformed by 12.61% the S&P500.




Analysts await Vivint Solar Inc (NYSE:VSLR) to report earnings on March, 15. They expect $-0.31 earnings per share, up 24.39% or $0.10 from last year’s $-0.41 per share. After $-0.33 actual earnings per share reported by Vivint Solar Inc for the previous quarter, Wall Street now forecasts -6.06% EPS growth.

Among 8 analysts covering Vivint Solar (NYSE:VSLR), 4 have Buy rating, 0 Sell and 4 Hold. Therefore 50% are positive. Vivint Solar has $45 highest and $3 lowest target. $4.92’s average target is 36.67% above currents $3.6 stock price. Vivint Solar had 19 analyst reports since July 21, 2015 according to SRatingsIntel. Deutsche Bank downgraded it to “Hold” rating and $5.5000 target in Wednesday, August 9 report. Goldman Sachs upgraded the shares of VSLR in report on Friday, October 7 to “Neutral” rating. The stock of Vivint Solar Inc (NYSE:VSLR) earned “Underperform” rating by Bank of America on Wednesday, April 20. The company was maintained on Thursday, March 17 by Credit Suisse. The firm has “Hold” rating by Deutsche Bank given on Wednesday, March 9. The firm has “Buy” rating by Deutsche Bank given on Friday, May 27. The stock of Vivint Solar Inc (NYSE:VSLR) earned “Mkt Perform” rating by JMP Securities on Thursday, September 8. The rating was downgraded by JMP Securities to “Market Perform” on Thursday, November 10. The rating was maintained by Goldman Sachs with “Sell” on Thursday, March 17. The stock of Vivint Solar Inc (NYSE:VSLR) earned “Market Perform” rating by Northland Capital on Tuesday, July 21.

Quentec Asset Management Llc, which manages about $578.63M and $1.30 billion US Long portfolio, upped its stake in Tesla Inc (Put) (NASDAQ:TSLA) by 109,100 shares to 354,100 shares, valued at $128.05M in 2017Q2, according to the filing. It also increased its holding in Micron Technology Inc (NASDAQ:MU) by 466,935 shares in the quarter, for a total of 2.03 million shares, and has risen its stake in Stmicroelectronics N V (NYSE:STM).

Investors sentiment decreased to 1.52 in Q2 2017. Its down 0.91, from 2.43 in 2017Q1. It dropped, as 12 investors sold VSLR shares while 11 reduced holdings. 16 funds opened positions while 19 raised stakes. 104.38 million shares or 0.85% more from 103.50 million shares in 2017Q1 were reported. Blackrock Incorporated accumulated 1.68M shares or 0% of the stock. American Intll Grp Inc Inc owns 16,156 shares. Quentec Asset Mngmt Lc holds 1.43% or 3.18M shares in its portfolio. State Street Corp has 363,520 shares for 0% of their portfolio. Raymond James Services Advisors stated it has 0% of its portfolio in Vivint Solar Inc (NYSE:VSLR). Vanguard Group Inc reported 1.74M shares. Bnp Paribas Arbitrage holds 2,823 shares. Federated Investors Pa holds 0% in Vivint Solar Inc (NYSE:VSLR) or 119 shares. Nationwide Fund holds 14,165 shares or 0% of its portfolio. Firsthand Inc invested in 0.07% or 12,000 shares. Ardsley Advisory Prns owns 394,800 shares or 0.41% of their US portfolio. Morgan Stanley has invested 0% in Vivint Solar Inc (NYSE:VSLR). Jpmorgan Chase & holds 0% in Vivint Solar Inc (NYSE:VSLR) or 47,530 shares. Manufacturers Life Ins Com The owns 5,684 shares. Moreover, Thompson Davis And has 0% invested in Vivint Solar Inc (NYSE:VSLR).

More notable recent Vivint Solar Inc (NYSE:VSLR) news were published by: Fool.com which released: “Why Vivint Solar Inc.’s Shares Popped 83% in June” on July 10, 2017, also Fool.com with their article: “Why Vivint Solar Inc.’s Shares Plunged 16% Today” published on September 25, 2017, Fool.com published: “Vivint Solar Expands Its Offerings With Storage and EV Charging” on September 14, 2017. More interesting news about Vivint Solar Inc (NYSE:VSLR) were released by: Bloomberg.com and their article: “Post-SunEdison Collapse, Vivint Solar Is Going Home Again” published on February 03, 2017 as well as Fool.com‘s news article titled: “Why Shares of Vivint Solar, Inc. Popped in October” with publication date: November 06, 2017.

Redmile Group Llc, which manages about $1.27B and $1.64 billion US Long portfolio, upped its stake in Inc Resh Hldgs Inc (NASDAQ:INCR) by 207,639 shares to 841,418 shares, valued at $49.22 million in 2017Q2, according to the filing. It also increased its holding in Model N Inc (NYSE:MODN) by 36,000 shares in the quarter, for a total of 858,314 shares, and has risen its stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH).

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals had 41 analyst reports since July 23, 2015 according to SRatingsIntel. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) earned “Buy” rating by RBC Capital Markets on Wednesday, November 1. The firm has “Buy” rating given on Wednesday, May 18 by Suntrust Robinson. The firm earned “Buy” rating on Tuesday, August 8 by Oppenheimer. Leerink Swann downgraded the shares of AGIO in report on Monday, December 7 to “Market Perform” rating. Cowen & Co maintained the shares of AGIO in report on Tuesday, August 8 with “Buy” rating. The rating was maintained by Roth Capital with “Neutral” on Monday, November 9. Leerink Swann upgraded the shares of AGIO in report on Wednesday, August 2 to “Outperform” rating. On Tuesday, June 6 the stock rating was maintained by Cowen & Co with “Buy”. Canaccord Genuity maintained Agios Pharmaceuticals Inc (NASDAQ:AGIO) on Monday, June 5 with “Buy” rating. The rating was maintained by SunTrust with “Buy” on Sunday, November 19.

More notable recent Agios Pharmaceuticals Inc (NASDAQ:AGIO) news were published by: Nasdaq.com which released: “Agios Posts New Data on Glioma Candidate from Dose Expansion” on November 20, 2017, also Prnewswire.com with their article: “Biotech Stock Performance Review — Achillion Pharma, Aduro BioTech, Agios …” published on November 20, 2017, Seekingalpha.com published: “Agios Pharmaceuticals’ (AGIO) CEO David Schenkein on Q3 2017 Results …” on November 01, 2017. More interesting news about Agios Pharmaceuticals Inc (NASDAQ:AGIO) were released by: Nasdaq.com and their article: “Agios Pharmaceuticals (AGIO) Q3 Earnings: What’s in Store?” published on October 27, 2017 as well as Nasdaq.com‘s news article titled: “Agios Pharmaceuticals Enters Oversold Territory (AGIO)” with publication date: November 20, 2017.

Since June 6, 2017, it had 0 insider purchases, and 2 selling transactions for $251,790 activity. Cantley Lewis Clayton Jr. also sold $101,730 worth of Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares.

Analysts await Agios Pharmaceuticals Inc (NASDAQ:AGIO) to report earnings on February, 15. They expect $-1.65 EPS, down 23.13% or $0.31 from last year’s $-1.34 per share. After $-1.59 actual EPS reported by Agios Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 3.77% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.